Comparison
Cagrilintide vs. MGF (Mechano Growth Factor)
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
1415456-99-3
12-Aminosäuren-C-terminales E-Domänen-Peptid (Sequenz nicht standardisiert)
Molecular weight
4253.7 g/mol
2867.2 g/mol
Half-life
168 h
0.1 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYYQPPSTNKNTKSQRRKGSTFEERKMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
MGF (Mechano Growth Factor)
The IGF-1 gene produces multiple isoforms by alternative splicing. IGF-1Ec is upregulated after mechanical muscle loading; the C-terminal E-domain is cleaved from the mature IGF-1 protein and appears to have independent effects on satellite cells. The exact receptor binding of the E-domain is not established; a classical IGF-1R effect is unlikely since mature IGF-1 is responsible. In cell-culture studies, stimulation of myoblast proliferation and differentiation has been observed.
Evidence base
Highest evidence
Human RCT
Animal model
Studies
4
4
of which in humans
3
0
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
1